s
The FDA’s Pharmacy Compounding Advisory Committee recently reviewed a group of peptides for possible inclusion on the 503A Bulk Drug Substances List. The committee supported adding several peptides, including BPC-157, KPV, TB-500, MOTs-c, Epitalon and Semax, according to recent legal/regulatory reporting. McDermott
Important: a committee recommendation is not the same thing as FDA approval. Formal FDA action/rulemaking is still required before a substance is actually added to the federal 503A bulk list. Stock Titan
That’s particularly important for the pages we’ve been working on. We should not automatically change “Not FDA-approved” to “FDA-approved” for these compounds.
BPC-157 is getting a lot of attention today
A new analysis reported today found a substantial increase in documented BPC-157 use from 2020 through 2026, despite limited human safety and efficacy evidence. Reuters reports that the number of newly identified users in the analyzed medical-record dataset increased 33-fold over that period. Reuters
The same report notes that an FDA advisory panel voted in July to support allowing pharmacy compounding of BPC-157. Again, that’s compounding access, not FDA approval of BPC-157 as a drug. Reuters
⚠️ But FDA enforcement against peptide vendors is still happening
This is the part I’d pay particularly close attention to for your website.
On August 24, 2026, FDA issued a warning letter to Peptide Partners after reviewing its website. FDA said products including semaglutide, tirzepatide, retatrutide, SS-31, tesamorelin and PT-141 were being marketed as unapproved new drugs because the website’s claims indicated intended human use. U.S. Food and Drug Administration
And this is extremely relevant:
FDA specifically stated that calling something “research use only” did not resolve the issue when the website’s actual claims suggested human use. FDA also considered the sale of bacteriostatic water alongside injectable peptides as evidence relevant to intended use.